Unique ID issued by UMIN | UMIN000012849 |
---|---|
Receipt number | R000015013 |
Scientific Title | Examination of utility of fulvestrant 500mg intended for climacteric junior line relapse breast cancer patient |
Date of disclosure of the study information | 2014/01/29 |
Last modified on | 2016/02/14 22:33:38 |
Examination of utility of fulvestrant 500mg intended for climacteric junior line relapse breast cancer patient
NGFBCS14-01
Examination of utility of fulvestrant 500mg intended for climacteric junior line relapse breast cancer patient
NGFBCS14-01
Japan |
ER-positive postmenopausal metastatic/inoperable breast cancer
Breast surgery |
Malignancy
NO
To evaluate the efficacy and safety of 500mg Fulvestrant therapy in patients with inoperable or metastatic ER-positibe postmenopausal breast cancer within 2-4 ET regimens.
Safety
Exploratory
Pragmatic
Not applicable
Clinical Benefit Rate(CBR)
Overall Response Rate(ORR)
Progression Free Survival (PFS)
Safety
Observational
Not applicable |
Not applicable |
Female
1. Patients who were histologically or cytologically diagnosed as inoperable/metastatic breast cancer.
2. ER-positibe in primary or metastatic lesions.
3.Patient of either of 1 for which endocrinotherapy is needed due to progress
relapse breast cancer as follows) -4).
1)Patient who relapsed within 12 months in supplementary treatment period of after the operation by endocrinotherapy or after supplementary treatment ends after the operation.
2)Patient where it relapses after 12 months or more have passed since supplementary treatment ended by endocrinotherapy after the operation, and progress was admitted for endocrinotherapy period afterwards.
3)Patient where progress was admitted for endocrinotherapy period as the first treatment to progress breast cancer patient.
4)Patient from whom progress was admitted in the 2nd or the third endocrinotherapy to progress/recurrence breast cancer
4. The 17th edition (June, 2012)/of the breast cancer handling rule Target (It is possible to measure it) change to a morbid state by the
RECIST standard (the 1.1th edition) is possessed.
5.Age 45-year-old or more postmenopausal women.
6. Written informed consent
1. Life threatening including
2.Inflammatory breast cancer
3. Allergy to fulvestrant.
4. Previous therapy by fulvestrant
5. Patients considered ineligible by the attending physician.
48
1st name | |
Middle name | |
Last name | Junichi Tobinaga |
JA Aichi Konan Kosei Hospital
Breast surgery
137 Omatsubara Takaya-cho Konan City Aichi Japan
0587-51-3333
j-tobinaga@konan.jaaikosei.or.jp
1st name | |
Middle name | |
Last name | Junichi Tobinaga |
JA Aichi Konan Kosei Hospital
Breast surgery
137 Omatsubara Takaya-cho Konan City Aichi Japan
0587-51-3333
j-tobinaga@konan.jaaikosei.or.jp
JA Aichi Konan Kosei Hospital
None
Self funding
NO
JA愛知厚生連 江南厚生病院 JA Aichi Konan Kosei Hospital
2014 | Year | 01 | Month | 29 | Day |
Unpublished
Preinitiation
2013 | Year | 11 | Month | 12 | Day |
2014 | Year | 01 | Month | 01 | Day |
2017 | Year | 09 | Month | 30 | Day |
2018 | Year | 04 | Month | 01 | Day |
2018 | Year | 05 | Month | 01 | Day |
2018 | Year | 06 | Month | 01 | Day |
None
2014 | Year | 01 | Month | 14 | Day |
2016 | Year | 02 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015013
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |